Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Februar 2023 02:00 ET | Quelle: Anaveon

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
10. September 2022 03:00 ET | Quelle: Anaveon

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
08. April 2022 13:00 ET | Quelle: Anaveon

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
16. Dezember 2021 02:00 ET | Quelle: Anaveon

Anaveon to raise CHF 110 million in oversubscribed Series B financing

- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...

Vorherige Seite